Accès ouvert
2025
article
OpenAlex
Priyanka D. Sehgal, Ammar S. Naqvi, Jia‐Geng Liu, Kyra Harvey et autres
To overcome the paucity of known tumor-specific surface antigens in pediatric high-grade glioma (pHGG), we contrasted splicing patterns in pHGGs and normal brain samples. Among alternative splicing events affecting extracellular protein domains, the most pervasive alteration was the skipping of ≤30-nt-long exons. …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jessica Foster, Peter J. Madsen, Kyra Harvey, Crystal Griffin et autres
BACKGROUND: Diffuse midline glioma (DMG) and high-grade glioma are devastating pediatric central nervous system tumors that remain incurable. Recent chimeric antigen receptor (CAR) T cell studies have shown proof of concept and early signs of efficacy against DMG targeting GD2. Prior work …
us, ch
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Priyanka D. Sehgal, Ammar S. Naqvi, Jia‐Geng Liu, Kyra Harvey et autres
SUMMARY To overcome the paucity of known tumor-specific surface antigens in pediatric high-grade glioma (pHGG), we contrasted splicing patterns in pHGGs and normal brain samples. Among alternative splicing events affecting extracellular protein domains, the most pervasive alteration was the skipping of ≤30 …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Stephanie Nicole Brosius, William Manley, Kyra Harvey, Jamie Galanaugh et autres
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Stephanie Nicole Brosius, William Manley, Kyra Harvey, Jamie Galanaugh et autres
Abstract BACKGROUND High-grade gliomas (HGG) represent the leading cause of cancer-related mortality in children due to a lack of curative therapies. Challenges of cellular therapies in brain tumors include the lack of unique tumor antigens, downregulation of targeted antigens, and immune suppressive …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Stephanie Nicole Brosius, William Manley, Kyra Harvey, Jamie Gallanaugh et autres
Abstract Glioblastoma has a poor prognosis with limited therapeutic options. To date, almost all therapeutic agents that showed promise in in vitro assays, preclinical trials, or even in early clinical trials have failed to make a substantial impact on the survival of …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Kyra Harvey, Katherine Labella, Angela Liou, Stephanie Nicole Brosius et autres
In vitro drug sensitivity screens are important tools in the discovery of anti-cancer drug combination therapies. Typically, these in vitro drug screens are performed on cells grown in a monolayer. However, these two-dimensional (2D) models are considered less accurate compared to three-dimensional …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Jessica Foster, Peter J. Madsen, Kyra Harvey, Luke Patterson et autres
Abstract Chimeric antigen receptor (CAR) T cells targeting the disialoganglioside GD2 have shown promise as a therapeutic for diffuse midline glioma (DMG). However, thalamic tumors have been excluded from clinical trials due to prior studies showing neurotoxicity and fatality when using virally …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Angela Liou, Deborah H. Moran, Jacquelyn M. Dougherty, Kyra Harvey et autres
Abstract BACKGROUND Pediatric High-Grade Gliomas (pHGG) are a significant cause of cancer-associated deaths in children. Hemispheric pHGG have frequent loss of the NF1 tumor suppressor (15%) causing aberrant RAS pathway activation. Intriguingly, loss of SETD2, a H3K36 methyltransferase, significantly co-occurs with loss …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Jacquelyn M. Dougherty, Kyra Harvey, Angela Liou, Katherine Labella et autres
Neurofibromatosis Type 1 (NF1) patients develop an array of benign and malignant tumors, of which Malignant Peripheral Nerve Sheath Tumors (MPNST) and High Grade Gliomas (HGG) have a dismal prognosis. About 15-20% of individuals with NF1 develop brain tumors and one third …
us
(code pays fourni par la source)